Last reviewed · How we verify
NCT06005714
Effect of Pharmacokinetics in Healthy Chinese Subjects
Phase 1 trial testing Mindeudesivir hydrobromide tablets and Clarithromycin tablets in The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects in 36 participants. Completed in 31 October 2023.
31 October 2023
Quick facts
| Lead sponsor | Shanghai Vinnerna Biosciences Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 36 |
| Start date | 15 August 2023 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Mindeudesivir hydrobromide tablets and Clarithromycin tablets — full drug profile →
- Mindeudesivir hydrobromide tablets and Cyclosporine softgels — full drug profile →
Conditions studied
- The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects — all drugs for The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects →
Sponsor
Shanghai Vinnerna Biosciences Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, open label, self-controlled phase I clinical study, to evaluate the effects of clarithromycin or cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets in healthy Chinese subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06005714
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Vinnerna Biosciences Co., Ltd. trials
Trials by the same sponsor.
- NCT06142201 — A Real-World Study of JT001 for COVID-19 · active not recruiting
- NCT06093230 — A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function · Phase 1 · completed
- NCT06093308 — A Study in Elderly Chinese Subjects With Underlying Diseases · Phase 1 · completed
- NCT05895812 — A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function · Phase 1 · completed
- NCT05802810 — The Mass Balance Study of [14C]JT001 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06005714 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Vinnerna Biosciences Co., Ltd.
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06005714.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing